Dyadic Reports Q3 2026 Financial Results with Significant Revenue Decline
Dyadic (DYAI) reported a sharp decline in third-quarter 2026 revenue, totaling approximately $449,000, which represents a 61% decrease year-over-year. This drop was primarily driven by a $538,000 reduction in grant revenue from programs such as the Bill & Melinda Gates Foundation and CEPI. Despite the revenue contraction, the company narrowed its net loss to $1.4 million ($0.04 per share) compared to a $2 million loss in the same period last year. The company's cash position stands at $6 million as of September 30, 2026, down from $8.6 million at the end of 2025, with an average monthly operating cash burn of approximately $590,000. On the operational front, Dyadic is focusing on its C1 proprietary fungal expression system, reporting successful yields for RSV and malaria antibodies and initiating direct product sales of recombinant transferrin and DNase 1.
Tickers: $DYAI
Topics: cash burn direct offering grant revenue net loss revenue decline